Damora TherapeuticsDMRA
13F holders, Q3 2025 (September 30)12holders +3
4new positions
1sold out
1famous investor
$3.72avg. 13F price*
At the end of Q3 2025, 12 institutions reported holding Damora Therapeutics Inc. (DMRA) in their 13F filings, up 3 from Q2 2025. 4 opened new positions and 1 sold out. The largest holders were Novo Holdings A/S ($322K), Connective Capital Management, LLC ($100K) and Two Sigma Investments, LP ($76K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Damora Therapeutics Inc.
- Filed as
- GALECTO INC (Q3 2025)
- CUSIP
- 36322Q206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $225K |
| Exits | 1 | $45K |
All 13F filers, Q2 2025 → Q3 2025: 66,680 shares bought and 29,235 shares sold, net +37,445 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Novo Holdings A/S | 0.02% | Reduce -13.3% | 86,579 | $322K |
| Connective Capital Management, LLC | 0.09% | New | 26,956 | $100K |
| Two Sigma Investments, LP | 0.00% | New | 20,296 | $76K |
| Renaissance Technologies | 0.00% | Add +3.4% | 15,044 | $56K |
| Virtu Financial LLC | 0.00% | New | 13,128 | $49K |
| Bank of America Corp. | 0.00% | Add +429.3% | 6,500 | $24K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +51.5% | 1,427 | $5K |
| BlackRock, Inc. | 0.00% | No change | 100 | $372 |
| UBS Group AG | 0.00% | Reduce -97.5% | 59 | $220 |
| Barclays PLC | 0.00% | Reduce -45.0% | 55 | $205 |
| Citigroup Inc. | 0.00% | New | 43 | $160 |
| SBI Securities Co., Ltd. | 0.00% | No change | 18 | $67 |
"% of holder's portfolio" is DMRA's weight in each manager's 13F, not the share of Damora Therapeutics Inc. the manager owns.